🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

Large holiday gatherings in U.S. not safe even if boosted, Fauci says

Published 12/22/2021, 04:20 PM
Updated 12/22/2021, 06:46 PM
© Reuters. FILE PHOTO: A general view of the U.S. Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia September 30, 2014. REUTERS/Tami Chappell
PFE
-

By Ahmed Aboulenein and Katharine Jackson

WASHINGTON (Reuters) - Americans vaccinated and boosted against COVID-19 can be with family over the holidays but attending large gatherings is not safe, even for those who received a booster dose, top U.S. infectious disease expert Anthony Fauci said on Wednesday.

The United States faces a second Christmas of upended holiday plans, with a surge in infections fueled by the now-dominant Omicron variant of the coronavirus forcing many to cancel travel, reconsider visiting loved ones, and question attending holiday parties.

"There are many of these parties that have 30, 40, 50 people in which you do not know the vaccination status of individuals. Those are the kind of functions in the context of Omicron that you do not want to go to," Fauci said at a White House briefing.

Early evidence indicates Omicron is less severe than the Delta variant, said Fauci, citing studies from South Africa and Scotland, but warned Americans must remain cautious.

"This is good news. However, we must wait to see what happens in our own population which has its own demographic considerations," he said.

The seven-day average of COVID-19 cases in the United States rose 25% from the previous week to about 149,300 cases per day, said U.S. Centers for Disease Control and Prevention Director Rochelle Walensky, with average daily deaths up 3.5% at 1,200.

Omicron represents approximately 73% of cases across the country, said Walensky, and as high as 90% of cases in some areas, such as the eastern Atlantic states, parts of the Midwest, South, and northern Pacific states.

"This increase in Omicron proportion is what we anticipated and what we have been preparing for," she said.

The U.S. government will have 265,000 treatment courses of Pfizer Inc (NYSE:PFE)'s COVID-19 anti-viral treatment available by January and 10 million by late summer, said White House COVID-19 response coordinator Jeff Zients.

© Reuters. FILE PHOTO: A general view of the U.S. Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia September 30, 2014. REUTERS/Tami Chappell

The Food and Drug Administration on Wednesday authorized Paxlovid, Pfizer's pill for at-risk people aged 12 and above.

The government will provide any resources Pfizer needs for production and will distribute treatments to states and localities at no charge as soon as they are delivered, he said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.